Cargando…

Targeting mesothelin in ovarian cancer

Detalles Bibliográficos
Autores principales:	Ghafoor, Azam, Thomas, Anish, Hassan, Raffit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	News
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281414/ https://www.ncbi.nlm.nih.gov/pubmed/30546824 http://dx.doi.org/10.18632/oncotarget.26350

Ejemplares similares

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results
por: Hassan, Raffit, et al.
Publicado: (2023)

Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors
por: Brockstedt, Dirk G, et al.
Publicado: (2013)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
por: Mazor, Ronit, et al.
Publicado: (2016)

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
por: Thomas, Anish, et al.
Publicado: (2015)

Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies
por: Zhan, Jingyu, et al.
Publicado: (2023)

The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
por: Hilliard, Tyvette S.
Publicado: (2018)

Safety and biodistribution of (111)In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging
por: Lindenberg, Liza, et al.
Publicado: (2015)

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
por: Zhang, Jingli, et al.
Publicado: (2014)

New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma
por: Zhang, Yi-Fan, et al.
Publicado: (2015)

Characterization of human mesothelin transcripts in ovarian and pancreatic cancer
por: Muminova, Zhanat E, et al.
Publicado: (2004)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Insights Into the Role of Mesothelin as a Diagnostic and Therapeutic Target in Ovarian Carcinoma
por: Shen, Jiayu, et al.
Publicado: (2020)

Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation
por: Coelho, Ricardo, et al.
Publicado: (2020)

High Homogeneity of Mesothelin Expression in Primary and Metastatic Ovarian Cancer
por: Weidemann, Sören, et al.
Publicado: (2023)

Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment
por: Hilliard, Tyvette S., et al.
Publicado: (2021)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets
por: Giordano, Giovanna, et al.
Publicado: (2022)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
por: Faust, Joshua R., et al.
Publicado: (2022)

Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells
por: Wang, Kun, et al.
Publicado: (2012)

High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
por: Cheng, W-F, et al.
Publicado: (2009)

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
por: Hassan, Raffit, et al.
Publicado: (2020)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma
por: Yu, Liping, et al.
Publicado: (2010)

Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
por: Zhao, Xiao-Yan, et al.
Publicado: (2016)

Amatuximab and novel agents targeting mesothelin for solid tumors
por: Baldo, Paolo, et al.
Publicado: (2017)

Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene
por: Ghafoor, Azam, et al.
Publicado: (2021)

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
por: Tomar, Sakshi, et al.
Publicado: (2022)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
por: Lv, Jiang, et al.
Publicado: (2019)

Mesothelin Expression Is Not Associated with the Presence of Cancer Stem Cell Markers SOX2 and ALDH1 in Ovarian Cancer
por: Nunes, Mariana, et al.
Publicado: (2022)

Synergistic Effect of a Mesothelin-Targeted (227)Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
por: Wickstroem, Katrine, et al.
Publicado: (2019)

Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors
por: Hatterer, Eric, et al.
Publicado: (2020)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_iooav0m9h7foeoek8qtkdmf6kd